Idun Pharmaceuticals
Pioneering therapeutic solutions to control apoptosis and advance treatments for liver disease, CNS disorders, inflammation, and cancer.
Pioneering therapeutic solutions to control apoptosis and advance treatments for liver disease, CNS disorders, inflammation, and cancer.
Idun Pharmaceuticals is a biopharmaceutical company that has been pioneering therapeutic solutions to control apoptosis and advance treatments for liver disease, CNS disorders, inflammation, and cancer. Established in 1993 and headquartered in San Diego, California, the company focuses on the discovery and development of human therapeutics to manage apoptosis. It has various products in Phase 2 and preclinical trials targeting liver disease, CNS diseases, inflammation, and cancer. Notably, IDN-6556 is developed to treat liver diseases in patients with Hepatitis C virus. The company received a $1.13M Debt Financing investment on 13 July 2015. IDUN Pharmaceuticals, Inc. now operates as a subsidiary of Conatus Pharmaceuticals Inc.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $1.13M | - | 13 Jul 2015 | |
| Venture Round | $2.00M | - | 09 Feb 2015 | |
| Series B | $27.00M | 9 |
|
15 Jun 2004 |
| Series A | $22.80M | 1 |
|
09 Dec 2002 |
| Seed Round | Unknown | - | 01 Jan 1995 |
No recent news or press coverage available for Idun Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
